Early application of Met-RANTES ameliorates chronic allograft nephropathy.
BACKGROUND
Initial insults to kidney allografts, characterized by infiltration of mononuclear inflammatory cells, contribute to chronic allograft nephropathy. Chemokines such as RANTES (regulated upon activation, normal T cell expressed) are thought to be responsible for the recruitment and activation of infiltrating cells. The present study investigated whether early application of Met-RANTES, a chemokine receptor antagonist that blocks the effects of RANTES, can protect renal allografts from long-term deterioration.


METHODS
Fisher (F344) rat kidneys were orthotopically transplanted into Lewis recipients and treated with cyclosporine A (1.5 mg/kg/day) for the first 10 days following transplantation, together with either Met-RANTES at 40 microg/day, 200 microg/day or vehicle for the first 7 days. Animals were harvested at 2 and 28 weeks after transplantation for histologic, immunohistologic and molecular analysis.


RESULTS
Met-RANTES treatment reduced the infiltration of lymphocytes and macrophages in allografts at 2 weeks after transplantation, accompanied by decreased mRNA expression of interleukin (IL)-2, IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and RANTES. At post-transplantation week 28, Met-RANTES treatment at high and low doses reduced urinary protein excretion and significantly ameliorated glomerulosclerosis, interstitial fibrosis, tubular atrophy, intimal proliferation of graft arteries and mononuclear cell infiltration. However, creatinine clearance was not influenced by Met-RANTES. Furthermore, Met-RANTES suppressed the mRNA expression of transforming growth factor-beta (TGF-beta) and platelet-derived growth factor-B (PDGF-B).


CONCLUSIONS
Blockade of chemokine receptors by Met-RANTES diminishes early infiltration and activation of mononuclear cells in the grafts, and thus reduces the pace of chronic allograft nephropathy.
Song
Erwei
E
Department of Nephrology, University Hospital, Essen, Germany.
Zou
Hequn
H
Yao
Yousheng
Y
Proudfoot
Amanda
A
Antus
Balazs
B
Liu
Shanying
S
Jens
Lutz
L
Heemann
Uwe
U
D000818:Animals; D001284:Atrophy; D001794:Blood Pressure; D001835:Body Weight; D002455:Cell Division / Q000187:drug effects; D018946:Chemokine CCL5 / Q000031:analogs & derivatives* / Q000235:genetics / Q000494:pharmacology*; D005355:Fibrosis; D015870:Gene Expression / Q000276:immunology; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D007375:Interleukin-1 / Q000235:genetics; D007376:Interleukin-2 / Q000235:genetics; D016030:Kidney Transplantation; D007684:Kidney Tubules / Q000473:pathology; D007962:Leukocytes / Q000276:immunology; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D011916:Rats, Inbred F344; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D018946:Chemokine CCL5; D007375:Interleukin-1; D007376:Interleukin-2; C108335:RANTES, Met-; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha